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Abstract
Background: Infection with human immunodeficiency virus (HIV) influences the outcome and natural disease
progression of hepatitis C virus (HCV) infection. While the majority of HCV mono-infected and HCV/HIV co-infected
subjects develop chronic HCV infection, 20–46% of mono- and co-infected subjects spontaneously clear HCV infection.
The mechanism underlying viral clearance is not clearly understood. Analysis of differential cellular gene expression
(mRNA) between HIV-infected patients with persistent HCV infection or spontaneous clearance could provide a unique
opportunity to decipher the mechanism of HCV clearance.
Methods: Plasma RNA from HIV/HCV co-infected subjects who cleared HCV and those who remained chronically
infected with HCV was sequenced using Ion Torrent technology. The sequencing results were analyzed to identify
transcripts that are associated with HCV clearance by measuring differential gene expression in HIV/HCV co-infected
subjects who cleared HCV and those who remained chronically infected with HCV.
Results: We have identified plasma mRNA, the levels of which are significantly elevated (at least 5 fold, False Discovery
Rate (FDR) <0.05) before HCV infection in subjects who cleared HCV compared to those who remained chronically
infected. Upon further analysis of these differentially expressed genes, before and after HCV infection, we found that
before HCV infection 12 genes were uniquely upregulated in the clearance group compared to the chronically infected
group. Importantly, a number of these 12 genes and their upstream regulators (such as CCL3, IL17D, LBP, SOCS3,
NFKBIL1, IRF) are associated with innate immune response functions.
Conclusions: These results suggest that subjects who spontaneously clear HCV may express these unique genes
associated with innate immune functions.
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Background
Hepatitis C virus (HCV) infection is the leading cause of
hepatocellular carcinoma in the United States [1]. Due
to similar transmission routes, approximately one third
of HIV-infected individuals are co-infected with HCV
[2–4]. In HCV mono infection, nearly 70–80% of in-
fected individuals develop chronic infection and liver
cirrhosis, some of whom develop hepatocellular carcin-
oma, while 20–30% of infected individuals spontaneously
clear the viral infection within one year of infection [5].
However, in HIV/HCV co-infected individuals, infection
with HIV is associated with a decrease in the rate of
spontaneous HCV clearance, exacerbates the natural
course of HCV infection, and accelerates the develop-
ment of HCC [6–10]. Currently, the mechanism of
spontaneous HCV clearance and how HIV might affect
this are not clear. Certain immunological components
have been shown to be involved in HCV clearance [11–13].
An HCV-specific T-cell response in the liver has also been
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reported to be associated with HCV clearance. Various
factors, such as gene polymorphisms in interleukin 28B
(IL28B) and IP-10 have been implicated in mediating host
susceptibility/resistance to HCV infection and disease pro-
gression [14–17]. In HCV-infected chimpanzees, interleu-
kin binding factor 3 (ILF3) and cytotoxic granule associated
cRNA binding protein (TIA1), which are associated with
robust T-cell responses, were highly induced in animals
who cleared the virus [18]. However, these represent only a
few of the many factors that are potentially involved in
HCV clearance.
Differential cellular gene expression in HIV-infected
subjects has been shown to be associated with HIV
disease progression [19]. Therefore, analysis of differential
cellular gene expression between HIV infected patients
with persistent HCV infection and those with spon-
taneous clearance of this virus could provide a unique
opportunity to decipher the mechanism of HCV clear-
ance in HIV/HCV co-infected subjects.
Pathogenic changes occurring in any tissues or organs
are expected to leave footprints in the blood. Conse-
quently, measurement of certain target RNA in the plasma
has been explored or used for diagnosis of a number of
diseases and cancers [20–24]. We hypothesize that the
cellular (immunological and non-immunological) factors
that are responsible for spontaneous HCV clearance leave
footprints in the plasma, leading to differential plasma
RNA expression profiles between those who spontan-
eously clear HCV infection and chronically infected indi-
viduals, with or without HIV co-infection. It is presumed
that differential gene expression in plasma between those
who cleared HCV and those who remained chronically in-
fected will provide clues to the mechanism of HCV clear-
ance. Due to the low quantity of RNA in blood plasma,
currently there is no convenient way to characterize plasma
RNA profiles. Recent advancement of next-generation
sequencing technologies has made it possible for unbiased
and comprehensive analysis of the gene expression from
both cells and tissues. We have recently modified the NGS
technology in Ion Proton platform and characterized RNA
profiles in plasma.
In this study we identified plasma mRNA, the levels of
which are significantly increased (at least 5 fold, FDR <0.05)
in the HCV clearance group compared to chronically HCV
infected patients. Upon further analysis of these differen-
tially expressed genes, we have identified 12 genes that are
upregulated only in clearance group before HCV infection.
Moreover, some of these 12 genes and their upstream regu-
lators are associated with innate immune functions.
Methods
Patients and samples
Frozen plasma samples were obtained from 13 HCV
seroconverters who were infected with HIV for more
than 10 years before HCV seroconversion in the Multi-
center AIDS Cohort Study (MACS) [25]. MACS is the
first and largest study specifically created to examine the
natural history of AIDS. MACS participants are seen
every six months and at each visit, plasma is taken for
storage at -80 °C. HCV seroconversion is defined by the
HCV antibody switching from negative to positive in
plasma and the plasma HCV antibody positivity were
persistent for all subsequent visits of the individuals.
Furthermore, HCV seroconversion visits were confirmed
by reverse transcriptase polymerase chain reaction specific
for detecting HCV RNA. Spontaneous HCV clearance is
defined as plasma HCV RNA were never detected or de-
tected only one to two times around the time of serocon-
version. Chronic HCV infection was defined as plasma
HCV RNA being persistently detected for more than five-
ten years. From five subjects with spontaneous HCV clear-
ance and eight subjects with chronic HCV infection, we
examined their plasma samples that were obtained imme-
diately before and after HCV infection (MACS visits are
six months apart). All HCV infections were reported to
have been acquired by sexual transmission. At the time of
HCV infection, all subjects were naïve to antiretroviral
therapy and anti-HCV treatment.
Nucleic acid extraction, cDNA library construction
and sequencing
Total nucleic acids were extracted from l ml of frozen
cryopreserved plasma using an automated NucliSens
EasyMag nucleic acid extraction machine (bioMérieux,
Durham, NC) followed by removal of DNA from the
nucleic extract with Qiagen AllPrep DNA/RNA mini
kit and ribosomal RNA by a Low Input RiboMinus
System (Life Technologies). The cDNA Library was
then constructed using an Ion Torrent Total RNA-Seq
Kit (Life Technologies) for whole transcriptome libraries
and Barcodes 1 through 8 from an Ion Xpress 1–16
barcoding kit were used (Life Technologies) for each indi-
vidual sample. cDNA libraries were quantified by qPCR
using an Ion Library Quantitation Kit (Life Technologies)
to determine a suitable template dilution factor for subse-
quent emulsion PCR and sequencing.
Four barcoded samples were combined for one se-
quencing reaction. Template preparation for sequencing
was conducted using the OneTouch Ion™ Template Kit
in the OneTouch machine (Life Technologies). Ion Tor-
rent sequencing was conducted using the Ion Proton
Sequencing Kit (Life Technologies) on an Ion Proton
Machine (Life Technologies) using a P1(v2)-chip (Life
Technologies). The constructed cDNA was also used
for HIV viral load measurement using a quantitative-
real time PCR for HIV gag RNA, with a sensitivity of 10
copies/mL [26].
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Sequence analysis
Raw sequencing reads in FastQ format were assessed for
quality using CLC Genomics Workbench 7. Reads were
accepted based on the length (longer than 25 nucleotides)
and number of ambiguous bases (Phred Quality Score
higher than 20). Quality trimming was performed. The
mean numbers of reads from different groups after trim-
ming ranged from 3.2 million to 8.4 million. The trimmed
reads were then mapped to Homo sapiens gene sequences
based on Homo sapiens (hg19) mRNA.
Bioconductor edgeR in R package was employed to
perform the differential expression analysis. A general
linear model was applied on the subjects before and
after HCV infection to accommodate the multifactor
design of the experiment. The model incorporates the
main effect for HCV infection plus interactions with pa-
tients and viral clearance, thus allowing us to identify
genes differentially expressed in HCV cleared and
chronically infected patients before and after HCV in-
fection. To ensure there were sufficient counts for each
gene in the test, genes with mean read counts higher than
10 were kept in the analysis. Genes with Benjamini-
Hochberg adjusted FDR <0.05 and fold change greater
than 1 were considered as significant genes. The signifi-
cance and function networks of the detected differentially
expressed genes were analyzed using Ingenuity Pathway
Analysis software. The gene function information was
obtained from GeneCards Human Gene Database
(www.genecards.org).
Results
Characteristics of study participants
A total of 26 plasma samples from the 13 HCV serocon-
verters obtained within six months before and after
HCV infection were analyzed for plasma transcriptome
profiles. All the participants were HIV positive for more
than 10 years before HCV infection occurred. Four of
the five participants who spontaneously cleared HCV in-
fection had the CC variant of the IL28B gene, while the
remaining one had the TT variant. In contrast, half of
eight participants who became chronically infected by
HCV had the CC variant IL28B gene and the remaining
participants had the CT variant. For the 5 individuals
with spontaneous HCV clearance, HCV loads were un-
detectable at the first HCV antibody positive visits. In
contrast, the eight participants with chronic HCV infec-
tion had a median plasma HCV load of 1.6x107 copies/ml
at the first HCV RNA positive visit, with values ranging
from 1.22 × 106 to 7 × 107 (Table 1). In the HCV clearance
group, the HIV viral load was below 40 copies/ml in three
of the five patients and > 71,000 copies/ml in two partici-
pants both before and after HCV seroconversion. In the
chronically HCV infected group, HIV viral load ranged
from 360 to 465,000 copies/ml (mean 125,233 copies/ml)
(Table 1).
Plasma mRNA profile of HIV-infected individuals with HCV
clearance and those with chronic infection
Plasma transcriptome analysis was performed in HCV
infected individuals who cleared virus and those who
remained chronically infected. A schematic diagram of the
approaches for measurement of differentially expressed
genes from the patients’ plasma samples collected before
and after HCV infection and those cleared HCV and those
who remained chronically infected is shown in Fig. 1. A
comparison of transcriptomes before HCV infection
Table 1 Clinical characteristics of the study subjects
HCV Clearance Group
Patient ID HCV infection HCV load HIV load Polymorphism of
IL28B gene
1 - <43 <40 CC
1 + <43 <40
2 - <43 <40 TT
2 + <43 <40
3 - <43 1,678,080 CC
3 + <43 3,598,880
4 - <43 71,680 CC
4 + <43 144,480
5 - <43 <40 CC
5 + <43 <40
HCV Chronic Infection Group
Patient ID HCV infection HCV load HIV load Polymorphism of
IL28B gene
11 - <43 129,080 CT
11 + 1.22x106 316,240
12 - <43 360 CT
12 + 70x106 50,840
13 - <43 81,240 CC
13 + 7.55x106 17,480
14 - <43 136,760 CC
14 + 3.93x106 1,040
15 - <43 73,840 CC
15 + 13.3x106 21,280
16 - <43 465,720 CT
16 + 18.9x106 170,120
17 - <43 138,520 CC
17 + 4.8x106 331,560
18 - <43 51,400 CT
18 + 7.33x106 18,240
Minimal detection limit of HIV measurement: 40 copies/ml
Minimal detection limit of HCV measurement: 43 copies/ml
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between the HCV clearance group (TR1B, Fig. 1) and
the chronically HCV infected group (TR 2B, Fig. 1)
showed that the expression levels of 32 genes were sig-
nificantly higher (5–563 fold) and expression level of
one gene (LL22NC03–63E9.3) was significantly lower
in the clearance group (Table 2). To further assess the
clustering of subjects within the chronic and clearance
groups and across the groups, hierarchical clustering
was performed using the differentially expressed genes
(Fig. 2a). Four of the eight chronically infected partici-
pants clustered together indicating a distinct gene ex-
pression pattern whereas the other four samples did
not show a similar pattern. On the other hand, three of
the five participants in the clearance group clustered
indicating similar gene expression and the remaining
two subjects had different gene expression. In both
clearance and chronic groups, the characteristics of the
samples that did not aggregate with the rest of the sam-
ples in the respective groups were not different with re-
spect to HIV viral load or IL28B polymorphism. This
suggests that HIV viral load and IL28B polymorphism
may not have an independent effect on the pattern of
the gene expression.
Of the 33 genes that were differentially expressed
(DEGs) before HCV infection, 19 DEGs have known
biological functions (Gene Cards Human Gene Database
(http://www.genecards.org/)): six gene products (18%)
(ATP6V1G2, LPAR1, GNAI1, CCL3, IL17D, SLC2A6)
are related to signal transduction pathways and innate
immune response,. eight gene products (24%) (LBR,
EARS2, RAB11FIP5, CHST10, PRPSAP1, PCMTD2,
MCU, PRDM13) are involved in metabolism and protein
trafficking, and five gene products (15%) (ZFHX3, DAZ4,
TLX3, HOXD13, NFKBIL1) are RNA/DNA binding pro-
teins involved in gene regulation (Fig. 2b).
To determine the differential gene expression pattern in
response to HCV infection, a similar analysis was per-
formed between transcriptomes in the clearance group
(TR1A, Fig. 1) and chronic infection group (TR2A, Fig. 1),
after HCV infection (Fig. 1). The expression levels of 56
genes were significantly higher, and that of one gene was
significantly lower, in TR1A compared to TR2A (Table 3).
Hierarchical clustering of DEGs showed that genes from
five patients who had chronic infection clustered together,
while no such clustering pattern was observed in the
clearance group (Fig. 3a).
Of the 56 DEGs in the HCV clearance group, 34 are
known to encode biologically functional proteins. Of
these 34 genes, 14 DEG gene products (25%) (MIXL1,
SLC30A3, SFRP5, NLRP13, IRS4, GNAI1, CMTM4, F10,
LPAR1, ATP12A, TLX3, ATP6V1G2, NEURL, AP3B1)
are known to participate in, or to be related to, signal trans-
duction pathways and innate immune responses, twelve
DEG gene products (21%) (LBR, MTMR1, PPP1R3G,
PRPSAP1, RAB11FIP5, MANEAL, MCU, ADPRHL1,
PRDM13, DPY19L3, SLC51A, CHST10) are involved in
metabolism and protein trafficking and eight DEG gene
products (14%) (ZFHX3, SOHLH1, TCF15, ZC3H8,
ZXDB, TLX3, HOXD13, ZXDA) are RNA/DNA binding
proteins involved in gene regulation (Fig. 3b). However,
no DEG was identified between plasma samples analyzed
before and after HCV infection, regardless whether they
were from clearance group (TR1B vs. TR1A) or chronic
group (TR 2B vs. TR 2A) (Fig. 1).
Intersection analyses between DEGs identified in the
clearance group before HCV infection (DEG-B, Fig. 1)
and after HCV infection (DEG-A, Fig. 1) indicate that
12 DEGs were uniquely expressed in clearance group
before HCV infection and 36 DEGs were uniquely
expressed after HCV infection (Fig. 4). There were 21
DEGs that were common between the two groups. IPA
analyses of these unique 12 genes expressed before
HCV infection indicate that a number of these genes
and their upstream regulators are associated with
innate immune response in the clearance group (Fig. 5a
and b). Among them 14% are involved in immune cell
trafficking, 14% are involved in humoral immune re-
sponse and 14% are involved in cell mediated immune
response suggesting that most of the unique DEGs in
the clearance group before infection may play a role in
defending against the virus (Fig. 5a). For instance, cyto-
kine (such as IL-1, IL-4, IL-6, IL-8, IL-9, IL-10, TNFR1,
interferon) signaling, Toll like receptor (TLR) signaling,
MAPK signaling, NF-κB signaling, and communication
between innate and adaptive immune cells may be in-
volved (Fig. 5b). Similar analyses with 36 DEGs after HCV
infection found that these genes are involved in gluco-
corticoid receptor signaling, myc mediated apoptosis sig-
naling, axonal guidance signaling, IGF1 signaling, MAPK
Fig. 1 Schematic diagram of the differentially expressed genes from
the patients’ plasma samples collected before and after HCV infection.
The sequences generated from the patients’ plasma RNA were
assessed by CLC Genomics Workbench 7 and statistically analyzed
using Bioconductor Edge R
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Table 2 DEGs in plasma before HCV infection in clearance group compared to those in chronically infected group
DEGsa Gene function Fold difference P value FDR
AD000091.2 Uncharacterized 563.4 2.83E–07 0.001188912
C11orf95 Chromosome 11 open reading frame 95. Diseases associated
with C11orf95 include ependymoma and chondroid lipoma.
100.9 5.80E–07 0.001188912
LPAR1 Lysophosphatidic acid receptor 1. Its related pathways are
PI3K-Akt signaling pathway and Ras signaling pathway.
20 6.66E–07 0.001188912
LBR Lamin B receptor. Its related pathways are Metabolism
and Metabolism.
20.6 2.85E–06 0.003815476
GNAI1 Guanine nucleotide binding protein (G protein), alpha inhibiting
activity polypeptide 1. Its related pathways are GPCR Pathway
and GPCR Pathway.
7.6 9.21E–06 0.008563212
HOXD13 Homeobox D13. This gene is related to sequence-specific DNA
binding transcription factor activity and chromatin binding.
231.4 9.61E–06 0.008563212
EARS2 Glutamyl-tRNA synthetase 2, mitochondrial. Its related pathways
are Metabolism and Gene Expression.
22.6 1.17E–05 0.008563212
PRDM13 PR domain containing 13. This gene related to
methyltransferase activity.
30.4 1.28E–05 0.008563212
RAB11FIP5 RAB11 family interacting protein 5 (class I). Its related pathways
are Endocytosis and Delta508-CFTR traffic/ER-to-Golgi in CF.
23 2.52E–05 0.013834245
CTC-504A5.1 Affiliated with the ncRNA class 16.6 2.58E–05 0.013834245
CHST10 Carbohydrate sulfotransferase 10. Its related pathways are
Other types of O-glycan biosynthesis and Biological oxidations.
8.9 4.28E–05 0.019890845
PRPSAP1 Phosphoribosyl pyrophosphate synthetase-associated protein 1.
This gene is related to magnesium ion binding and enzyme
inhibitor activity.
10 4.46E–05 0.019890845
TLX3 T-cell leukemia homeobox 3. Its related pathways are
Transcriptional misregulation in cancer and SIDS
Susceptibility Pathways.
103.6 5.11E–05 0.021040208
RP11-259G18.1 Uncharacterized 21.7 7.50E–05 0.024582733
DAZ4 Deleted in azoospermia 1. This gene is related to this gene
include RNA binding and nucleotide binding.
7 7.68E–05 0.024582733
TMEM52 Transmembrane protein 52 50.8 7.68E–05 0.024582733
AC007879.2 Uncharacterized 13.3 7.93E–05 0.024582733
PCMTD2 Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain
containing 2. This gene is related to protein-L-isoaspartate
(D-aspartate) O-methyltransferase activity.
10.4 8.26E–05 0.024582733
HNF1A-AS1 HNF1A antisense RNA 1 affiliated with the antisense RNA class. 13.6 8.86E–05 0.024984166
SUV420H2_1 Uncharacterized 21.7 9.76E–05 0.026140534
ATP6V1G2 ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2.
A multisubunit enzyme that mediates acidification of
intracellular compartments of eukaryotic cells.
27.3 1.06E–04 0.027114541
TCP10L T-complex 10-like. An important paralog of this gene is
TCP10L2.
13.9 1.23E–04 0.028632706
MCU Mitochondrial calcium uniporter. It is related to calcium
channel activity and uniporter activity.
7.8 1.23E–04 0.028632706
ZFHX3 Zinc finger homeobox 3. Its related pathways are Transcriptional
Regulatory Network in Embryonic Stem Cell.
8 1.59E–04 0.035570625
RP11-508 M8.1 Uncharacterized 10.7 1.85E–04 0.039536736
CCL3 Chemokine (C-C motif) ligand 3. Its related pathways are Signaling
by GPCR and TGF-Beta Pathway.
31 2.13E–04 0.043901777
LL22NC03-63E9.3 Uncharacterized LOC648691, affiliated with the ncRNA class. −22.2 2.30E–04 0.045120747
RP11-180P8.3 Uncharacterized 46.1 2.36E–04 0.045120747
RP11-213H15.3 Uncharacterized 11.1 2.56E–04 0.046011494
Chen et al. BMC Infectious Diseases  (2016) 16:693 Page 5 of 12
signaling, p53 signaling, PI3K/AKT signaling, and acute
phase response signaling.
Discussion
Unraveling the mechanism of spontaneous HCV clear-
ance after an acute phase of infection in HIV infected
individuals provides valuable information that will be in-
formative for the development of a vaccine against HCV.
In a genome-wide association study of HCV infected
individuals, SNPs in the region of the IL28B gene, en-
coding interferon-λ-3, were shown to be associated with
the outcome of HCV infection; the CC genotype enhances
spontaneous resolution of HCV infection, whereas those
with the TT genotype showed a great propensity to de-
velop chronic HCV infection [15, 16]. In the current study
we could not detect any significant relationship between
CC genotype and HCV clearance, because the CC geno-
type was found in four of the five clearance subjects and
four of the eight chronically HCV infected subjects. The
distribution of the genotypes in the infected subjects sug-
gests that other factors beside the IL28B SNPs play a role
in the spontaneous HCV clearance in the co-infected
individuals [14, 18, 27]. However, the small sample size
in our study also could explain our failure to detect an
association between IL28B polymorphisms and HCV
clearance.
Recent advances in RNA sequencing technology have
provided opportunities to comprehensively and quantita-
tively sequence RNA and examine virus-host interac-
tions at the transcriptional level. Two studies have
reported transcriptomes analysis of liver tissues of HCV
infected chimpanzees with spontaneous viral clearance
or chronic infection outcomes. Nanda et al [18] reported
that early induction of the genes associated with cell
proliferation and immune activation, especially interleu-
kin binding factor 3 (ILF3) and cytotoxic granule associ-
ated RNA binding protein (TIA1), was associated with
subsequent HCV clearance in infected chimpanzees.
Suet et al [28] reported that cellular genes induced by
IFN-γ and those involved in antigen processing/presen-
tation and the adaptive immune response were associ-
ated with HCV clearance. These reports suggest that
host innate/adaptive immune responses play an import-
ant role in HCV clearance. However, studies on the tran-
scriptome of liver tissues from HIV/HCV co-infected
Table 2 DEGs in plasma before HCV infection in clearance group compared to those in chronically infected group (Continued)
IL17D Interleukin 17D. Its related pathways are IL-17 Family
Signaling Pathways and IL-17 Family Signaling Pathways.
40 2.58E–04 0.046011494
AC016831.7 Uncharacterized 5.8 2.71E–04 0.04688832
NFKBIL1 Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor-like 1
8 2.98E–04 0.049193252
SLC2A6 Solute carrier family 2, member 6. Its related pathways are
PAK Pathway and HIF1Alpha Pathway.
7.9 3.03E–04 0.049193252
aDEG Differentially expressed gene
a b
Fig. 2 Differentially expressed genes before HCV infection in clearance group compared to chronic group. a The heatmap was generated with
the statistical differentially expressed genes between clearance group and chronic group before HCV infection. The numbers on X-axis represent
individual subjects. Green stands for the clearance group and blue stands for the chronic group. b Pie chart illustrates the percentage of the DEGs,
which encode proteins involved in different functions
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Table 3 DEGs in plasma after HCV infection in clearance group compared to those in chronically infected group
DEGsa Function Fold difference P value FDR
MIXL1 Mix paired-like homeobox. Among its related pathways are
Cardiac Progenitor differentiation and Adipogenesis.
142.7 3.52E–07 0.00142576
SLC30A3 Solute carrier family 30 (zinc transporter), member 3. Its related
pathways are Transport of glucose and other sugars, bile salts
and organic acids, metal ions and amine compounds and
Transport of glucose and other sugars, bile salts and organic
acids, metal ions and amine compounds.
23.8 5.32E–07 0.00142576
SFRP5 Secreted frizzled-related protein 5. Its related pathways are Wnt
signaling pathway (KEGG) (Wnt proteins are secreted morphogens
that are required for basic developmental processes) and
Non-Canonical Wnt Pathway.
53.4 2.05E–06 0.00365475
AC007879.2 Uncharacterized 13.8 1.45E–05 0.00595947
AD000091.2 Uncharacterized 283.2 1.05E–05 0.00595947
C12orf44 Autophagy related 101 18.9 8.91E–06 0.00595947
HNF1A-AS1 HNF1A antisense RNA 1 affiliated with the antisense RNA class. 48.4 1.32E–05 0.00595947
LBR Lamin B receptor. Its related pathways are Metabolism
and Metabolism.
70.9 1.36E–05 0.00595947
MTMR1 Myotubularin related protein 1. Its related pathways are
Metabolism and Metabolism.
20.4 1.44E–05 0.00595947
NLRP13 NLR family, pyrin domain containing 13 10.9 5.86E–06 0.00595947
PPP1R3G Protein phosphatase 1, regulatory subunit 3G. It is related to
protein phosphatase binding and glycogen binding.
82.1 1.25E–05 0.00595947
PRPSAP1 Phosphoribosyl pyrophosphate synthetase-associated protein 1.
This gene is related to magnesium ion binding and enzyme
inhibitor activity.
56.8 1.29E–05 0.00595947
RAB11FIP5 RAB11 family interacting protein 5 (class I). Its related pathways
are Endocytosis and Delta508-CFTR traffic / ER-to-Golgi in CF.
53.4 1.01E–05 0.00595947
RP11-436F21.1 Uncharacterized 9.6 1.93E–05 0.00740049
C11orf95 Chromosome 11 open reading frame 95. Diseases associated
with C11orf95 include ependymoma and chondroid lipoma.
119.4 2.56E–05 0.00913053
HOXD13 Homeobox D13. This gene is related to sequence-specific DNA
binding transcription factor activity and chromatin binding.
96 3.07E–05 0.01028157
RP11-508M8.1 Uncharacterized 14.6 3.46E–05 0.0109017
CTC-504A5.1 Affiliated with the ncRNA class 9.9 3.82E–05 0.01135634
IRS4 Insulin receptor substrate 4. Its related pathways are Signaling by
GPCR and Insulin receptor signaling cascade.
54.4 5.62E–05 0.01466991
MANEAL Mannosidase, endo-alpha-like. It is related to hydrolase activity. 14.7 5.95E–05 0.01466991
MCU Mitochondrial calcium uniporter. It is related to calcium channel
activity and uniporter activity.
11.9 6.03E–05 0.01466991
SUV420H2_1 Uncharacterized 18.4 5.71E–05 0.01466991
SLC25A18 Solute carrier family 25 (glutamate carrier), member 18. It is related
to this gene include symporter activity.
86.7 6.39E–05 0.01489091
GNAI1 Guanine nucleotide binding protein (G protein), alpha inhibiting
activity polypeptide 1. Its related pathways are GPCR Pathway
and GPCR Pathway.
10.8 6.69E–05 0.01492573
ADPRHL1 ADP-ribosylhydrolase like 1. It is related to magnesium ion binding
and ADP-ribosylarginine hydrolase activity.
7.3 9.39E–05 0.01676156
CMTM4 CKLF-like MARVEL transmembrane domain containing 4. It is related
to cytokine activity.
16 9.17E–05 0.01676156
F10 Coagulation factor X. it is related the pathways of Hemostasis and
Formation of Fibrin Clot (Clotting Cascade).
11.4 8.76E–05 0.01676156
LPAR1 Lysophosphatidic acid receptor 1. Its related pathways are
PI3K-Akt signaling pathway and Ras signaling pathway.
9.6 8.50E–05 0.01676156
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Table 3 DEGs in plasma after HCV infection in clearance group compared to those in chronically infected group (Continued)
LYSMD4 LysM, putative peptidoglycan-binding, domain containing 4 10.3 8.30E–05 0.01676156
RP11-886H22.1 Uncharacterized 9.3 9.38E–05 0.01676156
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide.
It is related to the pathways of Ion channel transport and
Transport of glucose and other sugars, bile salts and organic
acids, metal ions and amine compounds.
10.2 1.22E–04 0.01943478
POU4F1-AS1 RNF219 antisense RNA 1 8.1 1.23E–04 0.01943478
PRDM13 PR domain containing 13. This gene related to
methyltransferase activity.
30.5 1.23E–04 0.01943478
ZXDA Zinc finger, X-linked, duplicated A. it is related to sequence-specific
DNA binding transcription factor activity and C2H2 zinc finger
domain binding.
45.3 1.17E–04 0.01943478
AC009495.4 Uncharacterized 8.9 1.59E–04 0.02368413
RP11–410N8.1 Uncharacterized 29.8 1.55E–04 0.02368413
ANKRD34B Ankyrin repeat domain 34B 10.4 2.00E–04 0.02675171
DPY19L3 Dpy-19-like 3. It is related to transferase activity, transferring
glycosyl groups.
5.2 2.08E–04 0.02675171
LINC00609 long intergenic non-protein coding RNA 609 8.9 2.08E–04 0.02675171
RP11–180P8.3 Uncharacterized 96.5 2.15E–04 0.02675171
RP11–492E3.2 Uncharacterized −8.3 2.05E–04 0.02675171
TLX3 T-cell leukemia homeobox 3. Its related pathways are Transcriptional
misregulation in cancer and SIDS Susceptibility Pathways.
83.1 1.96E–04 0.02675171
ZFHX3 Zinc finger homeobox 3. Its related pathways are Transcriptional
Regulatory Network in Embryonic Stem Cell.
12.5 2.11E–04 0.02675171
SOHLH1 Spermatogenesis and oogenesis specific basic helix-loop-helix 1.
It is related to sequence-specific DNA binding transcription factor
activity and protein dimerization activity.
15.2 2.54E–04 0.03086759
SLC51A Solute carrier family 51, alpha subunit. It is related the Bile secretion
and Drug Induction of Bile Acid Pathway.
7.6 2.60E–04 0.03093234
TCF15 Transcription factor 15 (basic helix-loop-helix). It is related to ERK
Signaling and ERK Signaling pathways.
8.8 2.74E–04 0.03191743
RP11–118B18.1 Uncharacterized 6.5 3.08E–04 0.03504717
ATP6V1G2 ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2.
A multisubunit enzyme that mediates acidification of intracellular
compartments of eukaryotic cells.
23.3 3.68E–04 0.04059745
RP11–435M3.2 Uncharacterized 15.9 3.71E–04 0.04059745
C4orf32 A Protein Coding gene 4.4 4.10E–04 0.04218642
ZC3H8 Zinc finger CCCH-type containing 8. It is related to sequence-specific
DNA binding transcription factor activity and sequence-specific
DNA binding.
7 3.94E–04 0.04218642
ZXDB A protein coding gene. It is related to nucleic acid binding. 32.1 4.03E–04 0.04218642
CHST10 Carbohydrate sulfotransferase 10. Its related pathways are Other types
of O-glycan biosynthesis and Biological oxidations.
6.6 4.38E–04 0.04421968
RP11–7F17.5 Uncharacterized −5.1 4.50E–04 0.04426996
TMEM52 Transmembrane protein 52 108.9 4.55E–04 0.04426996
NEURL A Protein Coding gene. It is related the pathways of Signaling by
GPCR and Disease.
6 4.68E–04 0.0447815
AP3B1 A protein coding gene. It is related to the pathway of Lysosome
and Clathrin derived vesicle budding.
7.8 5.28E–04 0.04960697
aDEG differentially expressed gene
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humans with different outcomes are very limited. Due to
lack of available liver tissues, we focused on determining
transcriptomes in plasma from HIV/HCV co-infected
subjects with and without HCV clearance, since the
quantity and characteristics of RNAs in plasma may re-
flect concurrent pathogenic changes in host liver tissues.
The availability of sequential plasma samples with de-
fined onset and disease outcomes of HCV infection in
highly characterized HIV-infected subjects from the
MACS [25] provided us with a unique opportunity to
identify, for the first time, the cellular transcripts that
may be related to HCV clearance. Application of RNA
sequencing technology in plasma has allowed us to
determine such differentially expressed transcripts be-
tween subjects who cleared HCV and those who re-
mained chronically infected after acute infection. In
addition, the analysis of samples collected before and
after acquisition of HCV infection provided information
on cellular transcripts that may be associated with HCV
clearance. Plasma transcriptome analysis of mRNA in
subjects who cleared HCV and those who remained
chronically HCV infected before and after HCV infec-
tion identified 12 DEGs that are uniquely expressed be-
fore HCV infection and a number of these genes and
their upstream regulators are associated with innate im-
mune response in the clearance group. For instance,
a b
Fig. 3 Differentially expressed genes after HCV infection in clearance group compared to chronic group. a The heatmap was generated with the
statistical differentially expressed genes between clearance group and chronic group after HCV infection. The numbers on X-axis represent individual
subjects. Green stands for the clearance group and blue stands for the chronic group. b The pie chart illustrates the percentage of the DEGs, which
encode proteins involved in different functions
Fig. 4 Intersectional analysis of the differentially expressed genes before and after HCV infection in clearance group and Chronic group. The diagram
was generated with the statistical differentially expressed genes between clearance group and chronic group before and after HCV infection
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IL17D, a member of IL17 family, plays a major regula-
tory role in host defense and inflammatory diseases [29].
The NFKBIL1 gene encodes a divergent member of the
I-kappa-B family of proteins and is involved in the regu-
lation of innate immune response by negatively regulat-
ing TLR and interferon regulatory factor (IRF) signaling
pathways. In addition, the NFKBIL1 gene has a role in
negative regulation of transcriptional activation of NF-kB
genes in response to pro-inflammatory stimuli [30]. CCL3,
a chemokine, has been shown to increase NK activity [31].
This goes along with observation that subjects who re-
solved HCV infection had a higher frequency of HCV-
specific interferon-gamma-producing T-cells (P = 0.017)
and cytotoxic NK-cells (P = 0.005), compared to patients
who became chronically infected [27]. In addition, in
HCV infected patients treated with interferon-α and riba-
virin, increases in MIP-1α, MIP-1β and RANTES levels
after 24 h of treatment were exclusively observed in the
group that showed a sustained virological response, sug-
gesting an antiviral role of CCL3 [32]. Furthermore, IPA
analysis suggests that cytokine signaling (such as IL-1,
IL-4, IL-6, IL-8, IL-9, IL-10, TNFR1, interferon), TLR
signaling, MAPK signaling, NF-κB signaling, communi-
cation between innate and adaptive immune cells, and
ELF3 could be involved in HCV clearance.
Conclusions
Plasma RNA sequencing has identified the transcripts
that are significantly associated with HCV clearance and
are found to be expressed prior to infection. Some of the
transcripts are involved in innate immune function.
These results suggest that subjects who spontaneously
clear HCV may have the transcripts that modulate forms
of immunity that confer resistance to chronic infection
with HCV. Further studies with longitudinal samples
from HCV infected patients who cleared HCV infection,
and those who became chronically infected may provide




Fig. 5 Physiological system development and function of unique DEG in clearance group before infection. a Pie chart demonstrates that majority
of DEGs seen before HCV infection in the clearance group is clustered in immune mediated pathways. b Predicted interaction networks of mRNAs and
associated pathways were identified using the DEGs in clearance compared to chronic group before HCV infection. The interactions between genes
were identified using Ingenuity Pathway Analysis
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